Ekso Bionics® to Present and Exhibit at the 6th International Conference of Rehabilitation Medicine and Engineering in Shang...
May 18 2017 - 8:30AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced that the company will be presenting and
exhibiting at the 6th International Conference of Rehabilitation
Medicine and Engineering (CRME 2017), being held in Shanghai,
China, on May 20 – 21, 2017.
CRME 2017 is an annual meeting organized by
Shanghai Jiao Tong University and the National Rehabilitation Aids
Research Center to bring together well-known international experts
to discuss the rapid development and collaboration between
rehabilitative medicine and the digital age.
Ekso Bionics will present an overview of the
company and the clinical benefits of the EksoGT™, a wearable
exoskeleton device designed to rehabilitate patients with stroke
and spinal cord injuries.
The presentation details are as follows:
Presentation
Title: |
|
Ekso Bionics and the
Benefits of Robotic Rehabilitation |
Date: |
|
Saturday, May 20,
2017 |
Time: |
|
12:15pm –
1:15pm |
Location: |
|
Dahua Hongqiao Holiday
Inn Hotel, Yihua Hall, 2nd Floor |
Presenters: |
|
Josip Markus, Director,
Business Development, Ekso BionicsBarry Richards, EMEA Clinical
Director, Ekso Bionics |
“We are excited to showcase the EksoGT at this
international forum and to present the unique rehabilitation
benefits the technology provides,” commented Thomas Looby, Ekso
Bionics’ President and Chief Executive Officer. “China has the
world’s largest stroke and spinal cord injury patient populations,
but faces a shortage of licensed rehabilitation specialists.
This, in turn, has created a real need for new technologies, like
the EksoGT, to maximize care and improve patient outcomes.”
CRME 2017 attendees are also invited to see a
demonstration of the EksoGT and learn more about this innovative
technology at the Ekso Bionics booth, #A2.
For more information about Ekso Bionics or
EksoGT, visit www.eksobionics.com.
About EksoGT™EksoGT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of the
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 130
rehabilitation institutions around the world.
About Ekso Bionics®Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024